Aptamer Sciences Inc (KOSDAQ:291650)

-72.24% (1Y)

Market Cap	27.67B
Revenue (ttm)	1.08B
Net Income (ttm)	-8.70B
Shares Out	29.28M
EPS (ttm)	-494.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,837
Average Volume	260,957
Open	943.00
Previous Close	937.00
Day's Range	930.00 - 950.00
52-Week Range	842.00 - 4,015.00
Beta	0.42
RSI	46.49
Earnings Date	n/a

About Aptamer Sciences

Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. Aptamer Sciences Inc was founded in 2011 and is headquartered in Seongnam-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 291650

Financial Performance

In 2024, Aptamer Sciences's revenue was 1.08 billion, an increase of 345.26% compared to the previous year's 243.19 million. Losses were -8.70 billion, -36.02% less than in 2023.